From 1 May, a revolutionary cystic fibrosis medication, Trikafta, will become available to Australian children aged between 6 and 11 via the Pharmaceutical Benefits Scheme (PBS).

Cystic fibrosis is a genetic disorder that impacts 1 in 2,500 Australian newborns, causing a buildup of thick mucus in the lungs and other organs.

By providing access to Trikafta, more than 500 children each year are expected to benefit, with the medicine costing a maximum of $30 per prescription or $7.30 with a concession card. Without the subsidy, the medication could cost families more than $250,000 a year!

The Hon. Mark Butler MP, Minister for Health says “We know Trikafta changes lives and that’s why the Government moved as quickly as possible to make this treatment available for young Australians.”